Establishment of regional diagnostic reference level for CT planning of breast cancer and comparing them with international values

被引:0
|
作者
Hasanpour, E. [1 ,2 ]
Maziar, A. [1 ,2 ]
Paydar, R. [1 ,2 ]
Nikoofar, A. [3 ]
机构
[1] Iran Univ Med Sci, Fac Allied Med, Radiat Sci Dept, Tehran, Iran
[2] Iran Univ Med Sci, Radiat Biol Res Ctr, Tehran, Iran
[3] Iran Univ Med Sci, Sch Med, Dept Radiat Oncol, Tehran, Iran
来源
关键词
Radiotherapy; CT planning; breast cancer; Dose Reference Level; dose optimization; COMPUTED-TOMOGRAPHY EXAMINATIONS; RADIATION-DOSE OPTIMIZATION; THERAPY; CHEST; RADIOTHERAPY; ORGANS; ADULT; RISK;
D O I
10.61186/ijrr.22.4.999
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: All over the world, Computed Tomography (CT) scan is used as an essential method in radiation therapy treatment planning. Ionizing radiation for the medical exposures should follow principle "As Low as Reasonably Achievable" (ALARA) to reduce the dose. The objective of this study is to establish a Diagnostic Reference Level (DRL) for breast Computed Tomography planning (CTp) and compare it with other DRLs because there are no dose guidelines for breast cancer CTp in Iran. The established DRL can be used for dose optimization in CT planning. Materials and Methods: We surveyed six RT centers in Tehran and collected data from patients with breast cancer, who were of average size, regarding the volume Computed Tomography Dose Index (CTDIvol), the dose length product (DLP), the dose parameters, the scan length, the thickness of the slices, and the use of automated exposure control (AEC). DRLs were calculated for each dose descriptor using the rounded 75th percentile of the distribution of means. Results: Data were collected on a total of 90 breast cancer CT localization scans from six CT centers. Significant variation was observed in mean DLP and mean CTDIvol among centers (p value < 0.0001). Moreover, mean mAs and scan length significantly differed across centers (p < 0.0001). Calculated DRLs for breast localization are 296.29 mGy cm and 6.64 mGy for DLP and CTDIvol, respectively which were lower compared with other studies conducted in this field. Conclusion: There were differences in doses used for breast CT planning among centers. DRLs were proposed for dose optimization and patient radiation protection in CT planning.
引用
收藏
页数:10
相关论文
共 26 条
  • [21] Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study
    Gianluca Bottoni
    Francesco Fiz
    Matteo Puntoni
    Federica Matteucci
    Manuela Monti
    Andrea DeCensi
    Oriana Nanni
    Etienne Brain
    Jean Louis Alberini
    Bassam Dib
    Gianmauro Sacchetti
    Pierpaolo Trimboli
    Giorgio Treglia
    Nadia Harbeck
    Simona Sola
    Alessandra Gennari
    Arnoldo Piccardo
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 2477 - 2485
  • [22] Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study
    Bottoni, Gianluca
    Fiz, Francesco
    Puntoni, Matteo
    Matteucci, Federica
    Monti, Manuela
    DeCensi, Andrea
    Nanni, Oriana
    Brain, Etienne
    Alberini, Jean Louis
    Dib, Bassam
    Sacchetti, Gianmauro
    Trimboli, Pierpaolo
    Treglia, Giorgio
    Harbeck, Nadia
    Sola, Simona
    Gennari, Alessandra
    Piccardo, Arnoldo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (08) : 2477 - 2485
  • [23] INTERNATIONAL, MULTICENTRIC IN SILICO CLINICAL TRIAL IN LUNG, PROSTATE AND HEAD&NECK CANCER, COMPARING PHOTONS, PROTONS AND C-ION THERAPY TREATMENT: A MULTICENTRIC PLANNING STUDY BASED ON A REFERENCE DATASET OF PATIENTS: EVALUATION OF FEASIBILITY
    Jongen, R.
    Dekker, A.
    Qamhiyeh, S.
    Baumert, B.
    De Neve, W.
    de Meerleer, G.
    De Ruysscher, D.
    Eble, M.
    Engelsman, M.
    Fonteyne, V.
    Habrand, J. L.
    Kanematsu, N.
    Langendijk, H.
    Lomax, A.
    Madani, I.
    Masayuki, B.
    Matsufuji, N.
    Mazal, A.
    Oelfke, U.
    Schlegel, W.
    Tsujii, H.
    Verheij, M.
    Rasch, C.
    van de Water, T.
    Lambin, P.
    Pijls-Johannesma, M.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S95 - S96
  • [24] Challenging the current norm: Does health related quality of life data from reference populations accurately reflect baseline values in breast cancer patients? An observational cohort study comparing EORTC QLQ-C30 scores between the general Swedish population and baseline scores in breast cancer patients
    Sjokvist, O.
    Hakansson, S.
    Pantiora, E.
    Karakatsanis, A.
    EJSO, 2021, 47 (12): : 2971 - 2977
  • [25] ENDEAR: A randomized international phase 3 study comparing the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy vs placebo with paclitaxel in patients with advanced diagnostic-positive triple-negative breast cancer
    Dent, R.
    Schmid, P.
    Cortes, J.
    Kim, S-B
    Andre, F.
    Abramson, V.
    Cardoso, F.
    Colleoni, M.
    Morris, P.
    Steinberg, J.
    Tudor, I. C.
    Uppal, H.
    Paton, V. E.
    Peterson, A.
    Traina, T. A.
    CANCER RESEARCH, 2017, 77
  • [26] Assessing and Comparing the Diagnostic Effectiveness of [18F]FDG PET/CT and [18F]FDG PET/MRI for Distant Metastases in Breast Cancer Patients With Invasive Lobular Carcinoma Histology: An Ongoing Topic of Debate?
    Altundag, Kadri
    CLINICAL BREAST CANCER, 2025, 25 (01) : e99 - e99